Kidney Res Clin Pract.  2023 May;42(3):298-311. 10.23876/j.krcp.22.223.

Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility

• Damianaki A
• Stambolliu E
• Alexakou Z
• Petras D

• KMID: 2543785
• DOI: http://doi.org/10.23876/j.krcp.22.223

Abstract

Hemoperfusion has been considered a promising adjuvant treatment for chronic diseases and some acute states when specific removal of pathogenic factors from the bloodstream is desired. Over the years, advances in adsorption materials (e.g., new synthetic polymers, biomimetic coating, and matrixes with novel structures) have renewed scientific interest and expanded the potential therapeutic indications of hemoperfusion. There is growing evidence to suggest a prominent place for hemoperfusion as an adjuvant treatment in the setting of sepsis or severe coronavirus disease 2019 and as a therapeutic option for chronic complications associated with accumulated uremic toxins in patients with end-stage renal disease. This literature review will describe the principles, therapeutic perspectives, and the emerging role of hemoperfusion as a complementary therapy for patients with kidney disease.

Keyword

Adsorption; COVID-19; Hemodialysis; Hemoperfusion; Kidney diseases